Australia’s Acrux Biotech Set To Launch First Product In U.S.
This article was originally published in PharmAsia News
Executive Summary
Acrux Limited, an Australia-based biotech, is about to launch its first product in the United States, its hormone-replacement EvaMist (estradiol) to treat menopause. KV Pharmaceuticals is handling marketing expected to begin in a few weeks. The firms expect about $1.5 billion in annual sales in the United States. EvaMist delivers estrogen by being sprayed on the skin, a technique believed to be more convenient for women. ("Click here for more